France
· Delayed Price · Currency is EUR TME Pharma Statistics
Total Valuation
TME Pharma has a market cap or net worth of EUR 6.82 million. The enterprise value is 3.58 million.
| Market Cap | 6.82M |
| Enterprise Value | 3.58M |
Important Dates
The last earnings date was Wednesday, April 23, 2025.
| Earnings Date | Apr 23, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TME Pharma has 94.11 million shares outstanding. The number of shares has increased by 616.96% in one year.
| Current Share Class | 94.11M |
| Shares Outstanding | 94.11M |
| Shares Change (YoY) | +616.96% |
| Shares Change (QoQ) | +63.13% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.80% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 359.11 |
| PB Ratio | 4.23 |
| P/TBV Ratio | 4.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.63 |
| EV / Sales | 188.32 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.77 |
Financial Position
The company has a current ratio of 1.88
| Current Ratio | 1.88 |
| Quick Ratio | 1.83 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -292.11 |
Financial Efficiency
Return on equity (ROE) is -866.97% and return on invested capital (ROIC) is -264.38%.
| Return on Equity (ROE) | -866.97% |
| Return on Assets (ROA) | -111.45% |
| Return on Invested Capital (ROIC) | -264.38% |
| Return on Capital Employed (ROCE) | -325.77% |
| Revenue Per Employee | 1,583 |
| Profits Per Employee | -476,833 |
| Employee Count | 12 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -70.16% in the last 52 weeks. The beta is 1.50, so TME Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.50 |
| 52-Week Price Change | -70.16% |
| 50-Day Moving Average | 0.07 |
| 200-Day Moving Average | 0.10 |
| Relative Strength Index (RSI) | 56.00 |
| Average Volume (20 Days) | 719,150 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TME Pharma had revenue of EUR 19,000 and -5.72 million in losses. Loss per share was -0.16.
| Revenue | 19,000 |
| Gross Profit | 19,000 |
| Operating Income | -5.26M |
| Pretax Income | -5.72M |
| Net Income | -5.72M |
| EBITDA | -5.24M |
| EBIT | -5.26M |
| Loss Per Share | -0.16 |
Balance Sheet
The company has 3.25 million in cash and n/a in debt, giving a net cash position of 3.25 million or 0.03 per share.
| Cash & Cash Equivalents | 3.25M |
| Total Debt | n/a |
| Net Cash | 3.25M |
| Net Cash Per Share | 0.03 |
| Equity (Book Value) | 1.61M |
| Book Value Per Share | 0.02 |
| Working Capital | 1.57M |
Cash Flow
In the last 12 months, operating cash flow was -4.63 million and capital expenditures -16,000, giving a free cash flow of -4.65 million.
| Operating Cash Flow | -4.63M |
| Capital Expenditures | -16,000 |
| Free Cash Flow | -4.65M |
| FCF Per Share | -0.05 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -27,673.68% |
| Pretax Margin | -30,115.79% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TME Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -616.96% |
| Shareholder Yield | -616.96% |
| Earnings Yield | -83.86% |
| FCF Yield | -68.15% |
Stock Splits
The last stock split was on July 28, 2022. It was a reverse split with a ratio of 0.01.
| Last Split Date | Jul 28, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.01 |
Scores
TME Pharma has an Altman Z-Score of -84.75. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -84.75 |
| Piotroski F-Score | n/a |